We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Specialty-specific healthcare information technology leader Modernizing Medicine® today announced that current and future users of its electronic health records (EHR) system, EMA®, will have access to its real-time
Germany-based molecular testing company Qiagen has announced that it will receive $598,000 in funding from the US Department of Health and Human Services to develop a QIAstat-Dx respiratory
Biotechnology firm Medicortex Finland has commenced the third clinical trial of its diagnostic kit ProbTBI for detection of mild traumatic brain injury (TBI) and concussion in children. Medicortex
Israel-based medical device company Insightec has closed a $150m Series F financing round, led by Koch Disruptive Technologies (KDT) for its Exablate Neuro incisionless neurosurgery device. Koch Disruptive
US-based cardiac and vascular surgery company CryoLife has secured CE Mark for the On-X Ascending Aortic Prosthesis (AAP). The approval enables resumed distribution of the device in the
US-based medical devices manufacturer In2Bones Global has announced the launch of its Avenger Radial Head prosthesis system in the US. The company claims that the Avenger system is
Aria CV has received breakthrough device designation from the US Food and Drug Administration (FDA) for its medical device to treat pulmonary arterial hypertension (PAH). PAH is a
US-based medical technology firm Outset Medical has raised $125m funding to advance the commercialisation of its Tablo hemodialysis system. Based in Silicon Valley, Outset Medical is focused on
US-based medical device firm CardioFocus has submitted a pre-market approval (PMA) supplement to the US Food and Drug Administration (FDA) for the HeartLight X3 endoscopic ablation system to
Germany-based medical technology firm Siemens Healthineers has won a bid to become primary supplier for Quest Diagnostics immunoassay testing with Atellica solution. Under the terms of the multi-year